Research and development - Today Stories

Thermo Fisher Scientific, the world leader in serving science, and ChromSword, a provider of innovative software products, have collaborated to launch an automated high performance liquid chromatography (HPLC) and ultra-high performance liquid chromatography (UHPLC) method development system that enables chromatographers to deliver robust and validated methods in less time and with higher confidence. The new Thermo Scientific Vanquish Method Development HPLC and UHPLC system provides an integrated, network-deployable solution for automated method development and validation for diode-array, charged aerosol and mass spectrometric detection. Built for ease-of-use and speed, the system strategically combines the leading Vanquish HPLC and UHPLC systems and the Thermo Scientific Chromeleon Chrom…

Variants studied included Alpha, Beta, Gamma, Delta, Epsilon and Iota Majority of participants who received primary series maintain detectable binding and functional antibodies against variants for 6 months Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the publication of new data on the durability of the Moderna COVID-19 vaccine in generating neutralizing antibodies against variants of concern. The manuscript was published in Science. According to the paper, the majority of individuals vaccinated with the Moderna COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose. “We are pleased with these new data showing that people vaccinat…

Medicines Discovery Catapult (MDC) and We Share Ventures have embarked on a joint venture, piloting an innovative funding model aimed at opening new funding opportunities for early-stage medicines discovery. For too long, accessing catalytic funding has been a challenge for medicines discovery start-ups focused on areas of clinical unmet need. This impact-driven revolving funding model is the first of its kind in the sector and has the potential to create and sustain funding opportunities for medicines discovery start-ups focused on patient impact. The pilot brings together We Share’s innovative impact-driven revolving funding model with MDC Syndicate’s programme, enabling promising start-ups in the medicine discovery space access to long-term capital in the early phases of their growth. T…

BioMed X Institute to start two new research programs in the field of autoimmune diseases and drug delivery New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier Heidelberg, 02.08.2021. German independent research institute BioMed X announces today the start of two new research projects with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The start of these projects represents a major milestone in the strategic partners’ successful collaboration and addresses two challenging new research areas. Both collaborations were facilitated by Johnson & Johnson Innovation. The new research group PTA (‘Pro…

Byondis B.V., an independent, clinical stage biopharmaceutical company creating precision medicines, and Glycotope, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, have entered into a platform access agreement to discover and develop antibodies that target specific tumor-associated protein/carbohydrate combined glyco-epitopes (GlycoTargets). Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs). Specific financial terms have not been disclosed. “Selective tumor targeting is key to maximize the potential of our linker-drug platfo…

Translational Science Center for the Healthcare business sector to offer flexible ways of working coupled with the latest technology and equipment New Learning Center will bring all vocational training occupations together under one roof Both construction projects meet the highest sustainability requirements Merck, a leading science and technology company, plans to invest € 270 million at its global headquarters in Darmstadt by building a new Translational Science Center for its Healthcare business sector as well as a new Learning Center. The two construction projects are part of the € 1 billion investment package that Merck announced in March 2019 and plans to realize in Darmstadt by 2025. “Darmstadt is our site of the future. With these investments, we are underscoring the strategic im…

Bachem is pleased to announce that the company has been recognised as one of the five winners of the Swiss Biotech Success Stories Awards 2021. They have been recognised for the value that they have consistently achieved for the past 50 years — a success story based on quality, innovation, sustainability and technological leadership. The company has grown over 50% in the last five years —  operating with sites across the world — and now offer more than 5,500 different biologically active peptides, amino acid derivatives and oligonucleotides.  The prestigious awards, bestowed by the Swiss Biotech Association, celebrate those who have made important and sustainable contributions to the biotech industry in Switzerland. Selected success stories such as Bachem are showcased to illustrate how Sw…

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of its collaboration with My Green Lab, a non-profit organization committed to improving the environmental sustainability of scientific research. The company has set a goal to obtain Accountability, Consistency and Transparency (ACT) labelling for its entire cold temperature storage portfolio by the end of 2021. Over time, Thermo Fisher expects to ACT label more than 1,200 additional SKUs, enabling research, pharmaceutical and clinical laboratories to achieve their sustainability objectives by providing a broader range of purchasing options. "Our customers are committed to adopting more sustainable laboratory practices, and My Green Lab enables them to take proactive steps to meet th…

Thermo Fisher Scientific, the world leader in serving science, today announced a collaboration with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers. Through this agreement, Ortho Clinical Diagnostics customers will have complete access to MAS third-party quality controls as well as the LabLink xL web-based quality assurance program that provides real-time quality control monitoring with automatic data entry upload and audit-friendly reports. Customers will also have access to additional features, including support, service and quality control ranges for specific reagent lots, unique features that are not currently available through any other quality…

BioMed X Institute expands its collaboration with Merck KGaA, Darmstadt, Germany to a total of eight research programs. Call for application of the new research program ‘Extrachromosomal DNA in Cancer’ to open now. Heidelberg, Germany, July 5, 2021 – BioMed X, a leading independent research institute, announced today the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany. The new program will explore the role of extrachromosomal DNA in cancer and it will complement the research of two ongoing oncology programs at BioMed X in the fields of DNA damage response and RNA splicing. Extrachromosomal circular DNA (ecDNA) was recently found to be particularly abundant in multiple human cancer cells, although its frequency varies among different cancer types. Elevated l…

Aleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a collaboration to advance the early phase clinical development of Aleta’s CAR-T cell engagercandidate, ALETA-001. Aleta is a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, and Cancer Research UK is the world’s leading cancer charity dedicated to saving lives. Under the terms of the clinical development partnership, Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001, which will be led by Dr Amit Patel’s Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in Manchester, UK. ALETA-001 has been developed to benefit peo…

NEW YORK & LONDON, June 21, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, is pleased to announce the appointment of Dr. Kevin Schutz, PharmD, as Vice-President of Regulatory Affairs. Dr. Schutz will lead regulatory interactions related to clinical studies in the United States, Europe and Asian countries. Dr. Schutz has over 19 years of pharmaceutical industry experience including 14 years of Regulatory Affairs experience. He has focused on disease indications with high unmet medical needs, in Neurology (including multiple sclerosis), Pulmonology (including infectious disease), and other potential disease indications, which the Company is currently deve…

Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Eisai’s first ADC and combines Eisai’s in house developed anti-folate receptor alpha (FRα) antibody, and Eisai’s anticancer agent eribulin, using an enzyme cleavable linker. It is a potential best-in-class FRα ADC with a favorable pharmacology profile and demonstrated single agent activity in patients with advanced solid tumors. Eisai is currently investigating MORAb-202 in FRα-positive solid tumors (inclusive of endometrial, ovarian, lung and breast cancers) in two studies: a Phase 1 clinical study in Japan and a Pha…

Novo Holdings A/S, a leading global life sciences investor, today announced it has acquired BBI Group (“BBI”), a leading supplier of products and services to the global diagnostics and life sciences industries, from Exponent for an enterprise value of over GBP 400 million. Novo Holdings will be the majority shareholder of the company. Founded in 1986, BBI provides critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies to a global blue-chip customer base that includes Thermo-Fisher, Merck and Siemens. The company’s market-leading brand, BBI Solutions, provides a range of products, including antibodies, antigens, labels, complementary reagents and point of care tests. BBI is headquartered in South Wales a…

INTEGRATED PLATFORM APPROACH TO RESPOND TO THE CHALLENGES OF PANDEMIC PREPAREDNESS, RAPID RESPONSE AND DELIVERABILITY PRROTECT COMBINES FIRST-IN-CLASS PROGRAMMES ACROSS THERAPEUTIC MODALITIES, ACCELERATED R&D TIMELINES FOR HIGHLY EFFECTIVE NEUTRALISING ANTIBODIES WITH AI/ML PREDICTION TOOLS (J.HAL℠) AND MANUFACTURING PLATFORM (J.POD®) Hamburg, Germany, 15 June 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has launched an initiative for pandemic preparedness (“PRROTECT”). PRROTECT leverages a comprehensive set of novel projects and technologies to be better prepared for and respond faster to viral pandemics of the future. Virus outbreaks that can develop into dynamic pandemics are a permanent global threat. Besides p…

New agreement with Lonza will increase drug substance production in Europe by the fourth quarter 2021 Lonza Geleen will support the production of an additional 300 million doses per year Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has entered into an additional agreement with Lonza (SIX: LONN) to support drug substance manufacturing for its global supply chain. The agreement will establish a new production line at Lonza’s Geleen site in the Netherlands, contributing to the supply of an additional 300 million doses of Moderna’s updated booster variant vaccine candidate, if authorized, per year, at a 50 µg dose. In addition to previously announced investments in drug substance manufacturing with RO…

Bagsværd , Denmark and Tokyo, Japan, 1 June 2021 – Heartseed Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive worldwide collaboration and licence agreement for development, manufacturing and commercialisation of Heartseed’s lead asset HS-001. HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure. Heartseed is planning to initiate a phase 1/2 clinical trial in Japan (LAPiS Study) in the second half of 2021 evaluating the safety and efficacy of HS-001 for the treatment of heart failure caused by ischemic heart disease. Japan’s Pharmaceutical and Medical Devices Agency has approved Heartseed’s Clinical Tria…

Geneva, Switzerland, May 28, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100™ (aviptadil) in advanced clinical development to treat COVID-19 induced respiratory disorders, today announced the appointment of Taneli Jouhikainen, M.D., MBA, to the newly created position of Chief Operating Officer (COO), effective June 1, 2021. The position was created to stay abreast with Relief’s strategic transition from a clinical-stage company to a diversified, fully integrated product-driven entity. Dr. Jouhikainen will oversee all internal product development and intellectual property activities and will be an important contributor to the Company’s growth strategy and corporate development efforts. He…

Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced the global launch of PrisMax 2, the latest version of the company’s next-generation platform. PrisMax 2 is designed to help simplify delivery of continuous renal replacement therapy (CRRT) and other organ support therapies, while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU). The PrisMax 2 system features new solutions within the company’s TrueVue digital health portfolio, as well as the PrismaLung+ blood-gas exchanger that delivers extracorporeal carbon dioxide removal (ECCO2R) therapy to support the management of acute respiratory dysfunction. PrisMax 2 and TrueVue will soon be available in more than 20 countries across the United States and Europe. Prism…

The agreement will further enable global supply of mRNA-1273, Moderna’s COVID-19 vaccine with Samsung Biologics’ fill and finish manufacturing service May 22, 2021-- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract development and manufacturing service, today announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine. Upon execution of the deal, technology transfer will commence immediately at Samsung Biologics’ facilities in Incheon, South Korea, utilizing a state-of-the-art production line equip…